Sexually Transmitted Infections: Bacterial Vaginosis and External Genital Warts
A supplement to Ob.Gyn. News.
This supplement is sponsored by Boston University School of Medicine and it is supported by a restricted educational grant from 3M Pharmaceuticals. It is based on presentations made at a continuing medical education program held April 9-10, 2005, in Washington, DC.
To view the supplement, click the image above. To take the CME test, download and print out the PDF file, and follow the test instructions on page 8.
Contents
Course Director
Phillip G. Stubblefield, MD
Co-Director, Family Planning Clinical Care and Research Fellowship
Professor, Obstetrics and Gynecology
Boston University School of Medicine
Bacterial Vaginosis: Update on Pathogenesis and Treatment
Jane R. Schwebke, MD
Professor, Division of Infectious Diseases
University of Alabama at Birmingham, School of Medicine Received grant/research support from and is a consultant to 3M, KV Pharmaceutical Company, and Presutti Laboratories, LLC. Speaker's Bureau at 3M, KV, Pfizer Inc., and Presutti. She discusses the unlabeled use of metronidazole prophylaxis and tinidazole for the treatment of recurrent bacterial vaginosis.
Human Papillomavirus and Genital Warts: An Overview of Pathogenesis and Patient-Applied Therapies
Jennifer Gunter, MD
Assistant Professor, Obstetrics and Gynecology
University of Colorado Health Sciences Center
Denver Speaker's Bureau at 3M Pharmaceuticals. She discusses the unlabeled use of combination therapy with topical immunomodulators and cytodestructive techniques.
Target Audience
This activity has been developed for obstetricians/gynecologists and other healthcare professionals involved in the treatment of bacterial vaginosis and genital warts (condylomata acuminata).
Educational Needs
Bacterial vaginosis (BV) and human papillomavirus (HPV) infection, which can cause genital warts, are among the most common infections in women. The etiology of BV has not yet been established, but emerging evidence regarding the cause (or causes) of BV should lead to improved treatment strategies. Prompt diagnosis and treatment of BV are important to prevent gynecologic and obstetric complications, including preterm birth in pregnant women and postoperative complications following preterm birth in pregnant women and postoperative complications following gynecologic surgery. Accurate and early identification of HPV infection and education of patients regarding the risk factors associated with all sexually transmitted infections will help prevent the current widespread problem with transmission of HPV, human immunodeficiency virus, and numerous other viral and bacterial infections. Women's healthcare professionals need to have up-to-date information on pathogenesis, natural history, diagnosis, and treatment for each of these infections. This supplement provides a concise overview of those issues.
Learning Objectives
By reading and studying this supplement, participants should be able to:
• Discuss the findings of studies related to the pathogenesis of BV and HPV infection.
• Describe the current recommendations for the diagnosis of BV and HPV.
• List the currently approved treatment options for BV and HPV.
• Discuss the rationale for potential improvements in therapy for BV and HPV.
Accreditation
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent on the activity.
CME credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be sent within six weeks of receipt of the test answers to those who successfully complete the examination.
